Printer Friendly

Dysregulated Functions of Lung Macrophage Populations in COPD.

1. Lung Macrophage Populations in Mice and Humans

The lung is constantly exposed to the host's outer environment; therefore, constitutively active mechanisms are required to monitor for irritants and infections with pathogens. This pivotal sentinel function is assumed by lungresident immune cell populations including macrophages, dendritic cells (DCs), and airway epithelial cells [1]. To date, three major myeloid cell populations have been identified in the lung which differ in their exact localisation in the tissue and their developmental origin (Figure 1): resident alveolar macrophages (AMs), resident interstitial macrophages (IMs), and blood monocytes [2-4].

AMs reside in the airspaces of the lung, whereas IMs are found in the interstitial space between the alveoli and blood vessels. Morphological observation of these two populations indicated that AMs are larger in size than IMs [5]. In addition, phenotypic characterisation of AMs and IMs in mice revealed differences in the expression levels of MHC classII, CD11b, CD14, CD45, CD54, CD68, CD71, CD204, CD206, and Siglec-F [5-9]. Altogether, lung-resident macrophages have been characterized as CD11c+CD11bl[degrees] cells and can be distinguished from recruited cells during endotoxin or viral-induced inflammation by the level of CD11b expression [10]. In humans, AMs are described as [CD45.sup.+][CD206.sup.+][CD14.sup.lo][CD71.sup.+][CD169.sup.+] cells, whereas IMs are reported as [CD45.sup.+][CD206.sup.+][CD14.sup.hi][CD71.sup.-][CD169.sup.-] cells [11]. However, recently a study suggested high expression of the mannose receptor (CD206) in both macrophage populations and revealed two AM subpopulations with differential expression of the hemoglobin-haptoglobin complex scavenger receptor CD163 [12]. Lastly, Desch et al. found that human AMs ([CD206.sup.+][CD14.sup.lo]HLA- [DR.sup.+][CD64.sup.+][CD141.sup.+] cells) could be distinguished from lung tissue monocytes based on CD14 and CD16 surface expression [13].

Functionally, although a small fraction of AMs was shown to be present in lymph nodes in S. pneumoniae-infected mice [14], IMs are considered to be classical modulators of adaptive immunity in human and murine lungs [7, 15-18]. In humans and rodents, AMs have been reported to remove surfactants and debris [19], suppress adaptive immunity [20, 21], and regulate neutrophil and monocyte recruitment to the lung [22-24]. With regard to other typical macrophage functions, both populations display high phagocytic capacity [5, 25], but AMs are considered to be more potent phagocytes [17, 26-28] and they were shown to secrete proinflammatory mediators and reactive oxygen species (ROS) upon activation in animal studies [17, 27, 29, 30].

Research on both human and animal AMs challenged the homogeneity of this population [31, 32]. Instead, density-gradient centrifugation splits them into distinct subpopulations with differences in the expression of surface markers and intracellular enzymes as well as tumour lysis, migration, cytotoxicity, phagocytosis, lymphoproliferative response augmentation, soluble mediator release, and procoagulant activity [33-42].

Under steady-state conditions, the replenishment of AMs in humans and mice occurs mainly via self-renewal as recently demonstrated in long-term lung transplant, parabiosis, and fate-mapping studies [43-45]. During lung inflammation, a proportion of AMs dies by apoptosis and the cells are replenished in part by local proliferation of local stem cells, but also via the recruitment of blood mononuclear phagocytes [46-48]. IMs acquire proinflammatory markers upon activation, such as CD40, CD80, and CD86, and their numbers are increased in mice [6]. Between the two populations, AMs secrete more TNF-[alpha], but less IL-6, IL-1ra, and IL10 than IMs in rats [49]. Furthermore, in humans, the two populations exhibit differential sensitivity to pathogen recognition receptor (PRR) activation with IMs being less sensitive to TLR9 priming [5].

IMs are not a homogeneous population either, and in the rat lung interstitium, they are currently believed to be contaminated with up to 20% AMs [50]. Similar to AMs, several density-defined populations have been identified exhibiting differential prostaglandin secretion, migration, and phagocytosis capabilities [51-53]. It has long been considered that IMs are an intermediate step in maturation of infiltrating blood monocytes towards AMs [54, 55] because they display blunt lamellipodia and fewer lamellar inclusions than AMs and are morphologically more closely related to blood monocytes [4, 56, 57]. Moreover, in mice, they seem to proliferate more than AMs [17]. However, considering more recent findings in macrophage ontogeny and the possibility to measure hundreds to thousands of genes at the single cell level, these observations need to be revisited.

Monocytes are divided into subpopulations in both humans and mice (reviewed in [58]). Fate-mapping experiments in mice unraveled a [CD115.sup.+][CD11b.sup.+][Ly-6C.sup.hi][CCR2.sup.+] and a [CD115.sup.+][CD11b.sup.+][Ly-6C.sup.lo] monocyte population [59, 60]. [Ly-6C.sup.lo] monocytes express high levels of the fractalkine receptor [CX.sub.3]CR1, and they were shown to crawl inside blood vessels via lymphocyte function-associated antigen 1 interactions with the endothelial lining [60, 61]. Upon activation with an inflammatory stimulus, they rapidly respond by secreting TNF-[alpha] [62]. In contrast, [Ly-6C.sup.hi][CCR2.sup.+]C[X.sub.3][CR1.sup.- ][GR-1.sup.+] monocytes are actively recruited to inflamed tissues where they can differentiate into so-called inflammatory DCs or different flavours of macrophages [60, 63-65]. This subset was shown to express high levels of chemokine receptors, complement peptides, and annexins, while [Ly-6C.sup.lo] monocytes express more MHC class-II, growth factors, integrins, and scavenger receptors [66, 67].

In analogy to mice, human monocytes are divided into different subsets including [CD14.sup.++][CD16.sup.-] (classical), [CD14.sup.+] [CD16.sup.+] (intermediate), and [CD14.sup.-][CD16.sup.+] (nonclassical) [58]. All subsets are [CD206.sup.-][CD64.sup.+] [13] and express C[X.sub.3]CR1 and CXCR4 ([CD16.sup.+] monocytes express C[X.sub.3]CR1 at higher levels which allows them to adhere firmly to vessel walls [58]). Classical monocytes also express several CC chemokine receptors [58, 60] and are characterised by an antimicrobial phenotype [68]. Intermediate monocytes express genes related to antigen processing and presentation, transendothelial migration, and angiogenesis and secrete higher amounts of cytokines and ROS than other subsets [68, 69]. Human classical monocytes resemble murine [Ly-6C.sup.hi] monocytes, whereas nonclassical monocytes were described to be the counterparts of [Ly-6C.sup.lo] monocytes (reviewed in [64]). The human blood monocyte population structure was recently challenged by Villani et al. who, by application of single cell RNA sequencing, suggested that peripheral blood monocytes can be further divided in four subsets [70]. Whether this also holds true for lung monocytes awaits further investigation.

2. Chronic Obstructive Pulmonary Disease (COPD): Epidemiology, Pathology, and the Role of the Immune System

COPD is a chronic disease of the lower respiratory tract and is characterised by irreversible airway obstruction, chronic bronchitis, and loss of alveolar parenchyma (emphysema) [71]. It affects almost equally men and women, has its onset in midlife, and progresses slowly during adulthood [72] resulting in airway obstruction by mucus exudates and lung tissue remodelling [71]. Patients with COPD are diagnosed as stage 1 (mild) to 4 (very severe) based on spirometric grading as well as group A to D based on clinical assessment of symptoms and exacerbation risk according to GOLD classification [73]. Besides the well-documented increase in patients' disability-adjusted life years, COPD is also a huge economic burden for countries due to its chronic nature, the exacerbations which lead to patient hospitalisation and the lack of effective drugs [74-76].

COPD ranked sixth globally as a leading cause of death in 1990 and is projected to rank third by 2020 accounting for 7% of total deaths worldwide [73, 77, 78]. There are several causative factors for the disease (reviewed in [79,80]) including environmental factors, such as smoking (which is now accepted as the main causal factor of the disease), the use of biomass fuel, occupational exposure to toxic gases or dust, infections, outdoor pollution, genetic susceptibility as exemplified by the deficiency of [[alpha].sub.1]-antitrypsin (reviewed in [81]), and accelerated lung ageing [82, 83].

COPD is thought to be initiated when inhaled irritants activate innate immunity either directly by triggering common PRRs on immune and bronchial epithelial cells or indirectly by inducing the release of danger signals by epithelial and endothelial cells [84-86]. In fact, the subsequent recruitment of blood leukocytes and the destruction of lung tissue are TLR-dependent and macrophage activation occurs in an inflammasome-dependent manner [87]. Patients with COPD present with elevated levels of a broad range of proinflammatory mediators in their bronchial lavage, such as TNF-[alpha], IL-8, CCL2, CCL3, [LTB.sub.4], myeloperoxidase, and eosinophilic cationic protein among others [88-94]. In parallel, the vasculature upregulates surface adhesion molecules [95] and becomes permeable to attract blood neutrophils, monocytes, and eosinophils to the lung. Secretion of the tissue remodelling cytokine TGF-[beta] by epithelial cells has also been reported to relate to small airway obstruction in COPD [96].

Neutrophil percentages in COPD correlate with deterioration of lung function and airway obstruction [97] and, together with macrophages [98], they contribute to disease pathology via the production of extracellular matrix(ECM-) degrading enzymes [99]. Disintegrated alveolar wall components can be readily detected in the biological fluids of patients with COPD and are significantly higher than in healthy smokers [100]. Neutrophil elastase (NE) and metalloproteinases (MMPs) cause lung tissue destruction and trigger mucus secretion which obstructs small airways [101]. The imbalance between proteases and protease inhibitors in the lungs of patients with COPD causes enhanced chemotactic factor secretion by macrophages and further amplification of neutrophil recruitment [102].

In the healthy lung, DC sample inhaled exogenous material or apoptotic cells to induce immune tolerance or initiate appropriate immune responses [1]. In COPD, DCs accumulate in the lung in an IL-1[alpha]-dependent manner following a CCL20-CCR6 axis [103, 104]. Recent reports have suggested that the numbers of the various DC subsets are differentially altered in the several lung compartments. For example, Langerhans-type DCs have been observed selectively in small airways [105], whereas the numbers of bronchial mucosal DCs in the epithelium as well as the migratory CD83+ and CCR7+ DC subsets are reduced in patients with COPD [106, 107]. The dysregulated localisation of these immune cells comes together with altered immune responses regulated by the different subsets [108]; cigarette smoke and the lung inflammatory milieu decrease lung myeloid DC maturation [109, 110] and cause an imbalance to the costimulatory status of these cells [111]. In contrast, [CD1c.sup.+] DCs favour tolerogenic signalling and the induction of regulatory T cells [112]. DC-mediated [CD4.sup.+] T cell activation is predominantly skewed to a TH1 phenotype [113], although TH17 cells have also been found in the lungs of patients with COPD [114, 115]. However, in the epithelium, submucosa, and adventitia of peripheral airways of patients with COPD, CXCR3-expressing [CD8.sup.+] cells are the predominant T cell subtype [116]. [CD8.sup.+] lymphocytes contribute to tissue injury and cell death in the lung via the release of proteolytic enzymes, such as perforin and granzymes [117-120]. Finally, the numbers of regulatory T cells have been demonstrated to be in decline in patients with COPD in comparison with healthy smokers which highlights another causality factor for the chronicity of the disease [121,122]. Regarding the factors responsible for the increase in T cell numbers, Di Stefano et al. showed that IL-27 secretion by CD68+ cells in the BAL of patients with COPD may contribute to IFN-[gamma] and granzyme B secretion by [CD8.sup.+] lymphocytes as well as the induction of regulatory T cells [123]. However, more studies are needed to clarify the role of T cells as part of an efficient acute or a dysregulated chronic response mounted by alterations in innate immunity.

In 2006, the presence of B cells was also described in lymphoid follicles in small airways and lung parenchyma of patients with COPD and animal models [124]. Supporting evidence came from the detection of elevated levels of B cell-activating factor in lymphoid follicles which inversely correlated with lung function [125]. Although the nature of the antigens that activate B cells is not fully known, it has been speculated that they range from cigarette smoke irritants [126] to cell death and ECM degradation by-products, microbial components, and autoantigens [127].

Finally, a frequent manifestation of COPD is the colonisation of the patients' lungs by bacteria and viruses (likely due to impaired phagocytosis by AMs [126]) which cause exacerbations diminishing the patients' quality of life [128,129]. H. influenzae, S. pneumoniae, and M. catarrhalis are most usually detected in patients with frequent exacerbations, while P. aeruginosa infections account for exacerbations in patients with severe COPD [130-132]. Furthermore, in recent years, the role of viral infections in the worsening of patients' health has begun to be appreciated and research has focused on the identification of the immune cells and mechanisms that contribute to the loss of lung function. Rhinoviruses [133], picornavirus [134], adenoviruses, the respiratory syncytial virus, and influenza virus are the most common viruses found in the sputum of patients with COPD and are responsible for about half of all exacerbations observed (reviewed in [135]). Infections augment the innate immune responses and lung tissue remodelling in mice [136], while human patients present with dysregulated neutrophil and T cell mobilisation [89, 137], increased proinflammatory mediator levels [138, 139], and antibacterial humoral responses [140].

3. Why the Functions of Lung Macrophage Populations in COPD Warrant Further Investigation

The numbers of lung-resident macrophages in the lung have been reported to be dramatically increased in COPD due to the recruitment of blood leukocytes from the periphery [141, 142]. Macrophages are plastic cells and respond in several ways to accommodate changes in their microenvironment. For example, AMs from smokers present with increased expression of cytokines and chemokines, growth factors, proteases, antioxidant proteins, adhesion molecules, transcription regulators, and signalling pathway genes, whereas they reduce expression of genes related to neutrophil activation, serine protease inhibitors, and macrophage differentiation genes [143]. Consequently, in the constantly changing microenvironment of the COPD lung, resident macrophages will respond accordingly and shape their effector functions to orchestrate the immune responses. Hence, the study of the functions of lung macrophage populations as well as their interplay with other immune cells and the lung stroma has the potential to enhance our understanding of COPD pathology and provide with novel biomarkers and therapeutic targets.

4. AMs in COPD

Over the last decades, numerous studies have accumulated knowledge about the role and functions of AMs in COPD. Major aspects of change in cellular functions concern the secretion of proinflammatory mediators, the induction of oxidative stress, the deregulation of the protease-protease inhibitor balance, and the impairment of pathogen phagocytosis as well as changes in gene expression which we highlight next (Figure 2 and Table 1). Many of these studies have been performed in the pregenomic era and most of them prior to the era of single cell genomics. Therefore, as for every other field in life sciences, some of the previous findings might be challenged once we have applied cutting-edge technologies to better understand the basic unit of life--the cell--and its changed functionality in complex diseases like COPD. Nevertheless, we review the current knowledge which has often been obtained only at the population level, but not at the single cell level yet.

4.1. Altered Secretion of Proinflammatory Mediators. AMs from patients with COPD present with alterations in the secretion of cytokines and chemokines. In particular, the levels of TNF-[alpha], IL-1[beta], IL-6, IL-10, IL-12, CCL2, CCL5, CCL7, CCL13, CCL22, IL-8, CXCL9, and CXCL10 in AM secretions from smokers were significantly different from healthy subjects [126, 144-152]. Similarly, the levels of the chemokine receptors CCR2 and CCR5 were found to be increased [153, 154]. Moreover, macrophages primed with endotoxin and cigarette smoke presented with delayed IL-1[beta] and IL-6 secretion in comparison with control endotoxin-treated cells and a subsequent increase in IL-8 levels [155]. Finally, sputum macrophages from patients with COPD were found to express more prostaglandin H synthases 1 and 2 than unaffected control subjects [156].

TLR signalling is pivotal for proinflammatory mediator secretion by macrophages in COPD as exemplified by the TLR4-dependent cigarette smoke-mediated activation of human macrophages [157]. Downstream of TLR activation, lung macrophages from patients with COPD also exhibit dysregulated signalling including p38, ERK1/2, JNK and IRAK-1 phosphorylation, I[kappa]B[alpha] expression, and NF-[kappa]B p65 activation compared to healthy individuals [145, 147, 155]. Finally, the importance of TLR signalling for macrophage proinflammatory mediator secretion in COPD is also illustrated by the downregulation of the chemokines CXCL9, CXCL10, and CXCL11 [147,154,158] as a result of the attenuation of TLR3 activation [158]. While all these findings are very informative, we still do not have an integrative, systemic, and causal model of the main regulatory mechanisms operative in AMs of patients with COPD.

Therefore, more light needs to be shed on the molecular programmers that drive these functional differences and conclude whether these are observed in a fraction of the AM population. To this end, microRNAs have been involved in the regulation of proinflammatory cytokine release by AMs [159], whereas recent investigation into the epigenetic networks active in macrophage populations of patients with COPD and healthy smokers revealed that the histone deacetylases HDAC2 and HDAC3 are downregulated in comparison with healthy individuals and correlate negatively with disease severity [160, 161]. Similarly, Yang et al. showed that oxidative stress induces posttranslational modifications on HDAC2 which are responsible for the loss of function of this enzyme's activity [162]. Taken together, it seems plausible to hypothesise that defects in the transcriptional and epigenetic regulation of proinflammatory genes in COPD cause dysregulated TLR signalling and effector biomolecule secretion by AMs.

4.2. Induced Oxidative Stress. Inhaled cigarette smoke and airborne pollutants induce oxidative stress in human lungs. In more detail, cigarette smoke contains approximately 4000 chemicals including oxidants which impact lung physiology [163, 164]. On the contrary, the antioxidant protein glutathione (GSH) is heavily suppressed [150,165] in macrophages by the actions of aldehydes in cigarette smoke [166] and biomolecules are modified (e.g., protein carbonylation) [147] leading to deleterious effects on living cells.

In response, AMs from patients with COPD have been demonstrated to express the nitrite synthase gene iNOS, but less heme oxygenase 1 (HO-1) than healthy smokers [167]. As mentioned above, other inflammation-related molecules, such as the histone deacetylases HDAC2 and SIRT1, are downregulated in AMs in an oxidative stress-dependent manner [165, 168, 169]. Eventually, cigarette smoke-induced oxidative stress and subsequent downstream gene expression changes in AMs result in Bak/Bax and cytochrome c-dependent apoptosis [170] increasing the cell debris pool that needs to be removed from the lung tissue to prevent secondary inflammation.

Finally, iron metabolism is dysregulated in the lungs of patients with COPD. Iron regulatory protein 2 and hemosiderin overexpression cause cellular and mitochondrial deposition of iron in alveolar tissue and resident macrophages which is associated with neutrophilia and infective exacerbations [171, 172]. Indeed, a recent report showcased the enhanced nutrient uptake and storage in AMs from patients with COPD. Philippot et al. found that these cells present with increased transferrin and ferritin expression important for iron uptake and storage [173]. Iron-loaded AMs from smokers also secrete higher amounts of ferritin than nonsmokers [174, 175] which could catalyse oxidative stress reactions in the alveolar tissue.

It has become apparent that exacerbated oxidative stress in AMs of patients with COPD impacts on other physiological pathways. For instance, oxidation of phospholipids in AMs impairs bacterial intracellular killing in mice [176]. To date, investigation of such concepts with available analytical tools is challenging. On the contrary, whole transcriptome analysis approaches complemented by bioinformatic coexpression network analysis would allow to link the expression patterns of dysregulated oxidative stress genes to the rest of the transcriptome in order to uncover overlooked interconnected biological pathways.

4.3. Deregulation of the Protease-Protease Inhibitor Balance. COPD progression correlates with the persistent activation of AMs and changes in the balance of secreted proteases and protease inhibitors (Figure 2). The importance of these molecules was illustrated in an experimental model of COPD where macrophage infiltration and the expression of proinflammatory mediators were induced in response to released mast cell-tryptases [177, 178].

ECM degradation enzymes, such as MMPs and cathepsins, are produced by macrophages and result in elastolysis and alveolar tissue damage [179-182]. Furthermore, these proteases have the potential to cleave small proteins and expose chemotactic fragments or they act as chemoattractants themselves and perpetuate macrophage accumulation in the lungs [183, 184]. On the contrary, cigarette smoking has been shown to induce the functional inactivation of a1antitrypsin, a NE inhibitor, which leaves smokers vulnerable to lung tissue destruction [185].

Monocytes and AMs are potent producers of several proteases; MMPs including MMP-1, MMP-2, MMP-7, MMP-9, and MMP-12, and cathepsins, such as K, L, B, and S, [180, 181, 184, 186, 187] and study have documented the overexpression of MMP-1, MMP-2, MMP-7, MMP-9, and MMP-12 in the lungs of smokers compared to healthy individuals [154, 188-194].

In patients with COPD, the expression of MMP-9 by AMs was shown to coincide with that of tissue inhibitor of metalloproteinases 1. The balance of these two mediators can be detrimental for the level of tissue damage in COPD lung and is controlled by the anti-inflammatory cytokine IL-10 [195]. Additional evidence for the current consensus of protease-protease inhibitor deregulation in macrophages from patients with COPD was provided by the fact that human patients with the most common a1-antitrypsin mutation have greater proteolytic activity partially due to higher expression levels of the membrane-bound serine protease matriptase [196].

Furthermore, patients with COPD have more MMP-12positive macrophages than healthy individuals in their lungs [193]. Macrophages are the main source of MMP-12 in the lungs of emphysematous mice [113, 182], and this MMP was shown to be important for connective tissue breakdown and neutrophil recruitment [99]. The mechanism MMP-12 utilises to promote inflammation was shown to involve the cleavage of the TNF precursor on the surface of macrophages and its release to the lung microenvironment [197].

Lastly, a perhaps not so well-documented function of AMs in COPD is their chitinolytic activity. Chitinases are released in the bronchoalveolar fluid of patients and are over-expressed by AMs from patients with COPD [198]. The presence of chitinase 1 and YKL-40, a chitin-binding protein, was found to correlate with airway obstruction and emphysema and to promote the production of proinflammatory mediators, such as cytokines, chemokines, and proteases by AMs from patients with COPD [198-200]. To date, we do not fully understand whether the upregulation in the expression of chitinases by AMs is a specific immune response against fungal opportunistic infection of patients with COPD and this warrants further investigation.

Given the significance of the protease activation pathway in irreversible tissue damage, it is necessary to understand how protease and protease inhibitor production is regulated in AMs aiming to fully characterise potentially defective molecular pathways that are responsible for the imbalance in the release of these mediators. Moreover, the literature is often contradicting with regard to the identity of protease members expressed by AMs. Currently available genomic techniques could settle the discrepancy noticed between older and more recent reports and show whether genetic polymorphisms account for the deregulation of protease-protease inhibitor imbalance in AMs.

4.4. Impaired Pathogen Phagocytosis. Due to their strategic localisation at the host-environment interface, AMs are key players in sensing microbes and irritants and initiating the phagocytosis process in order to remove and destroy them. Macrophage phagocytosis in patients with COPD has been extensively studied in humans and animal models, and our current understanding is that AMs present with a phagocytosis defect when treated with air pollutants (Figure 2) [201, 202].

AMs from patients with COPD and cigarette smoke-treated animals have been reported to display impaired phagocytosis of pathogens, such as H. influenzae [203-207], C. albicans [208, 209], E. coli, M. catarrhalis [206, 207], and S. pneumoniae [205, 206, 210] compared to controls. Interestingly, defective phagocytosis of latex particles has only been described for murine AMs which implies that data generated from different species should be taken with caution [211]. It is not entirely clear whether the inability of macrophages to efficiently uptake foreign material is tissue-specific or whether it is the result of a global genetic defect. For instance, in some studies, monocyte-mediated phagocytosis was comparable with that of AMs [204], whereas in others monocytes from patients with COPD demonstrated dysregulated phagocytic abilities [212], especially when the subjects were diagnosed with acute bronchopneumonia [213]. Therefore, further work is needed to determine whether the suppressed macrophage phagocytic capacity in patients with COPD is governed by lung-specific factors.

Besides phagocytosis of external stimuli, macrophages are also responsible for the clearance of accumulating apoptotic cells to avoid the release of toxic intracellular substances which can cause secondary inflammation and inhibit tissue repair [214]. This process, coined efferocytosis, has been suggested by some studies to be compromised in AMs from patients with COPD when coincubated with apoptotic neutrophils [215, 216], eosinophils [217], or epithelial cells [150, 218, 219]. Moreover, AMs from cigarette smokers upregulate the apoptotic cell removal tyrosine kinase MERTK, arguably in a compensation mechanism to restore endogenous efferocytosis levels [220]. Interestingly, macrophage efferocytosis index was reversed in AMs from animals and patients with COPD treated with native a1-antitrypsin implying a relationship between the protease-protease inhibitor balance and apoptotic cell engulfment [221]. Moreover, mechanistic data provided by a number of groups support the idea that an increased expression of genes of the sphingosine-1 phosphate system can explain the defective efferocytic responses of AMs [222-225], although it is currently unclear whether other lipid metabolism pathways also play a role.

Studies designed to provide an insight into the molecular mechanisms that account for the suppressed AM efferocytosis showed that the expression of recognition receptors, such as CD31, CD44, CD91 [219], CR-3, CR-4, Fc[gamma]R1, MARCO, and DC-SIGN, was significantly changed in AMs from patients with COPD [150, 226]. However, the expression of recognition molecules was found to be similar between smokers and patients with COPD in other reports contradicting the original findings [205]. In another report, the expression of the macrophage scavenger receptor 1 in monocyte-derived macrophages was associated with genetic variants which also controlled in vitro cell adhesion and survival in culture [227]. Finally, conflicting data have been published concerning the involvement of p38, ERK1/2, PI3K, ROCK, and p65 kinases and cytoskeletal changes in AM phagocytosis in COPD [147, 228].

Recently, Richens et al. showed that Rac1 activation inhibits RhoA kinase resulting in actin rearrangement and lamellipodia protrusion [229], while Minematsu et al. confirmed that RAC1 and VAV1 kinase levels are reduced in cigarette smoke-treated macrophages [216]. Therefore, it is possible that the compromised phagocytic/efferocytic capacity of macrophages in COPD can be partially explained by impaired effector kinase signalling. Finally, Bewley et al. recently showed that the defective intracellular pathogen killing exhibited by AMs from patients with COPD is caused by a MCL-1-mediated failure to increase mitochondrial ROS production [230]. Collectively, while enormous progress has been made in understanding the molecular mechanisms of altered phagocytosis in COPD, we still do not have an integrated model of the pathophysiological changes operative in AMs in this disease.

4.5. Surface and Intracellular Marker Expression. To date, the assessment of AM surface marker expression in patients with COPD has focused on classical M1/M2 markers [231, 232], while our own work clearly indicated that this outdated classification cannot be applied to macrophages in COPD [144]. AMs from patients with COPD express less costimulatory molecules, such as the T cell activation and survival signalling molecule CD80, major histocompatibility antigens [150, 233], Fcy receptors and integrins on their surface [234], more CD163, and carbohydrate and lipid scavenger receptors, such as CD206 and CD204 than non-COPD smokers and nonsmokers [235].

Similarly, as already indicated above, the expression of surface PRRs is modulated in patients with COPD; TLR2, TLR4, and TLR5 are expressed at lower levels in macrophages from patients with COPD [126, 148, 236, 237]. However, there is contradicting evidence regarding the regulation of TLR2 expression which suggests that more work is needed to delineate whether this PRR and subsequent downstream signalling pathways play a role in the functional differences observed between macrophages from healthy individuals and patients with COPD. In contrast to the aforementioned receptors, TLR3 expression as well as downstream effector molecules, such as IL-8 and MMP-9, are overexpressed in macrophages in COPD [238]. Furthermore, polymorphisms in certain PRRs, such as TLR9, are associated with the compromised proinflammatory mediator secretion described above [206]. Lastly, patients with COPD have more CD163+ macrophages in their lungs [239] which is most likely the consequence of lung microenvironment imprinting, as incubation of a human macrophage cell line with sputum from patients with acute exacerbation of COPD induced the expression of other anti-inflammatory genes, such as CD206 and arginase in vitro [240].

5. IMs and Monocytes in COPD

The literature has mainly focused on the role that AMs play in COPD. However, not much is known about the functions of IMs in the lung or monocytes in the blood (Figure 2 and Table 2). In mice, inhaled smoke causes an accumulation of C[X.sub.3]CR1+ monocytes and lung macrophages which associate with lung inflammation [241]. Monocytes infiltrate the lung and were shown to replace the dying resident macrophages [242]. In particular, C[X.sub.3][CR1.sup.-][GR-1.sup.hi] monocytes undergo a differentiation step into C[X.sub.3][CR1.sup.+][GR-1.sup.lo] cells before subsequently differentiating into lung macrophages after an inflammatory insult or the depletion of lung-resident macrophages [243]. Whether this is also the case for humans remains an open question.

Monocytes are believed to develop into lung parenchyma macrophages which in mice have been identified as C[X.sub.3][CR1.sup.hi][CD11b.sup.+][CD11c.sup.hi][MHC-II.sup.hi] macrophages and express TNF-[alpha] and IL-6 [244]. More evidence for the presence of monocytes in the human lung during inflammatory diseases came from the characterisation of a [CD14.sup.+][HLA-DR.sup.+] macrophage population in the sputum of patients with COPD capable to produce high levels of TNF-[alpha] [245]. In the lung, recruited monocytes have been shown to modulate neutrophil infiltration via the secretion of proinflammatory mediators [246].

Similar to AMs, monocyte activation in patients with COPD presents with gene expression signatures related to apoptosis, protease function, proliferation and differentiation, glycerol metabolism, and cytosolic transport as shown by a microarray study [247]. As a result of their activation state, monocytes display more prominent migration towards CCL5, CXCL1, CXCL7, or CXCR3 chemokine gradients [248, 249], production of IL-6 and CCL2, but less IL-8, MMP-9, and CD54 compared to controls [146]. In contrast, the literature on phagocytosis by monocytes from healthy individuals and patients with COPD is contradictory [205, 250]. With regard to MMP production, Perez-Rial et al. showed that the recruited monocytes are responsible for the overall increase of macrophage numbers in a murine model of COPD [251]. Interestingly, monocyte/macrophage responses depend a lot on the causative agent of COPD as exemplified in a diesel exhaust particle-induced study where monocytes exhibited less CXCL8 and phagocytic responses due to dampened CD11b, CD14, and CD86 surface expression [252], while they overexpress CCR2 in smokers [253].

There have been various mechanistic lines of evidence to explain the augmented proinflammatory phenotype of monocytes; Dang et al., for example, found that miRNA expression, such as miR-24-3p and miR-93-5p, correlates with dysregulated downstream TLR and NOD-like receptor signalling proteins, such as I[kappa]B[alpha] [254]. On top of that, altered epigenetic cues as exemplified by the downregulation of HDAC levels cause an upregulation in proinflammatory gene expression and NF-[kappa]B-mediated inflammation [160, 255].

6. Concluding Remarks

COPD affects around 328 million people worldwide, and it is projected to rank within the top four most fatal diseases by 2030 [77, 256]. Moreover, the chronic nature of the disease and the frequently observed exacerbations and comorbidities have major consequences on patients' lives and countries' economic status [256]. It is therefore important to advance our knowledge of immune system manifestations in COPD and uncover the molecular pathways responsible for the cross talk between immune cells and the lung stroma in order to provide the clinic with prognosis/diagnosis biomarkers and the pharmaceutical industry with novel testable genes/ pathways for future drug development screenings.

Already in 1979, it had been suggested that the macrophage population, which comprises of lung-resident macrophages and blood monocytes, constitutes more than 97% of all cells in the human bronchoalveolar lavage [257], while two decades later, the severity in COPD was linked to the presence of macrophages, neutrophils, NK cells, and activated epithelial cells in the lung [258]. However, due to the lack of specific markers and respective technologies at that time, no further subset specifications or functional subdivision could be performed and these studies remained incomplete. This is also true for studies which suggested correlation between COPD severity or small airway infiltration and macrophages [259-261] and reports which demonstrated less apoptosis and more proliferation in AMs from smokers [262]. Taken together, many of the findings concerning the role of certain immune cells and their relation to disease state, severity, and outcome have been obtained more than two decades ago. While still of value, these findings are challenged by very recent findings concerning cellular classification and function of immune cells in general.

With regard to lung macrophage populations, the efforts to better appreciate their role in COPD remain elusive. AMs are the only lung-resident macrophage population that has been extensively investigated in the past, whereas IMs have long been considered solely as an intermediate step in monocyte differentiation mainly due to limitations associated with their harvest from human subjects. The field is missing out on valuable information about potentially existing homogeneous macrophage subsets with distinct phenotypes associated with a pathological feature or clinical subgroup of COPD. In addition, the molecular mechanisms that dictate the functions of lung macrophage populations remain poorly characterised; for example, although there is evidence that the dysfunctions of lung macrophages in COPD are regulated epigenetically, an unbiased evaluation of the interplay between transcription factors and epigenetic networks active in lung macrophages in COPD is currently lacking.

To this end, latest advances in the fields of Immunogenomics and Systems Biology have been very encouraging and can help address these open questions (Figure 3). The deconvolution of the lung macrophage structure with high-dimensional single cell technologies, such as RNA sequencing, could identify lung-resident macrophage subpopulations with unique transcriptomes that reflect the niche, activation state, or interactions with other immune cells at the time of harvest [232]. Subset-specific genes could then be associated with a COPD subgroup and be validated with mass cytometry. Such an approach could stratify COPD patient cohorts according to new biomarkers and replace currently used symptom-based readouts [263].

Furthermore, the early discovery of HDAC downregulation in patients with COPD should be followed up by complementary assay for transposase-accessible chromatin (ATAC) sequencing to predict complex networks of histone-modifying enzymes and transcription factors that direct transcription in lung macrophages and link them to certain genes/biological functions [232]. Subsequent chromatin immunoprecipitation (ChIP) sequencing would validate these targets and lead to new hypothesis generation and potentially novel therapeutic interventions.

To conclude, there are many exciting research avenues to be followed, now supported by genetic and computational approaches made available in the last decade. The high level of macrophage plasticity in vivo implies that there are complex stimulatory and regulatory molecular circuits that act simultaneously and result in their physiological dynamics. Hence, to better understand the role lung macrophages play in COPD, we will need to take advantage of these novel tools and revisit older findings.

Abbreviations
AM:     Alveolar macrophage
ATAC:   Assay for transposase-accessible chromatin
COPD:   Chronic obstructive pulmonary disease
ChIP:   Chromatin immunoprecipitation
DC:     Dendritic cell
ECM:    Extracellular matrix
GSH:    Glutathione
HO-1:   Heme oxygenase 1
IM:     Interstitial macrophage
MMP:    Metalloproteinase
NE:     Neutrophil elastase
PRR:    Pathogen recognition receptor
ROS:    Reactive oxygen species.


https://doi.org/10.1155/2018/2349045

Conflicts of Interest

The authors declare no conflicts of interest. Joachim L. Schultze is a member of the Excellence Cluster Immuno-Sensation.

Acknowledgments

This work was supported by the German Research Foundation to Joachim L. Schultze (SFB704, Excellence Cluster ImmunoSensation).

References

[1] M. Kopf, C. Schneider, and S. P. Nobs, "The development and function of lung-resident macrophages and dendritic cells," Nature Immunology, vol. 16, no. 1, pp. 36-44, 2014.

[2] B. E. Lehnert, "Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung," Environmental Health Perspectives, vol. 97, pp. 17-46, 1992.

[3] R. E. Crowell, E. Heaphy, Y. E. Valdez, C. Mold, and B. E. Lehnert, "Alveolar nd interstitial macrophage populations in the murine lung," Experimental Lung Research, vol. 18, no. 4, pp. 435-446, 1992.

[4] S. Y. S. Tan and M. A. Krasnow, "Developmental origin of lung macrophage diversity," Development, vol. 143, no. 8, pp. 1318-1327, 2016.

[5] J. Hoppstadter, B. Diesel, R. Zarbock et al., "Differential cell reaction upon Toll-like receptor 4 and 9 activation in human alveolar and lung interstitial macrophages," Respiratory Research, vol. 11, no. 1, p. 124, 2010.

[6] A. V. Misharin, L. Morales-Nebreda, G. M. Mutlu, G. R. S. Budinger, and H. Perlman, "Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung," American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 4, pp. 503-510, 2013.

[7] R. Zaynagetdinov, T. P. Sherrill, P. L. Kendall et al., "Identification of myeloid cell subsets in murine lungs using flow cytometry," American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 2, pp. 180-189, 2013.

[8] Y. Feng and H. Mao, "Expression and preliminary functional analysis of Siglec-F on mouse macrophages," Journal of Zhejiang University SCIENCE B, vol. 13, no. 5, pp. 386-394, 2012.

[9] A. Johansson, M. Lundborg, C. M. Skold et al., "Functional, morphological, and phenotypical differences between rat alveolar and interstitial macrophages," American Journal of Respiratory Cell and Molecular Biology, vol. 16, no. 5, pp. 582-588, 1997.

[10] M. Duan, W. C. Li, R. Vlahos, M. J. Maxwell, G. P. Anderson, and M. L. Hibbs, "Distinct macrophage subpopulations characterize acute infection and chronic inflammatory lung disease," The Journal of Immunology, vol. 189, no. 2, pp. 946-955, 2012.

[11] Y.-R. A. Yu, D. F. Hotten, Y. Malakhau et al., "Flow cytometric analysis of myeloid cells in human blood, bronchoalveolar lavage, and lung tissues," American Journal of Respiratory Cell and Molecular Biology, vol. 54, no. 1, pp. 13-24, 2016.

[12] A. Bharat, S. M. Bhorade, L. Morales-Nebreda et al., "Flow cytometry reveals similarities between lung macrophages in humans and mice," American Journal of Respiratory Cell and Molecular Biology, vol. 54, no. 1, pp. 147-149, 2016.

[13] A. N. Desch, S. L. Gibbings, R. Goyal et al., "Flow cytometric analysis of mononuclear phagocytes in nondiseased human lung and lung-draining lymph nodes," American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 6, pp. 614-626, 2016.

[14] A. C. Kirby, M. C. Coles, and P. M. Kaye, "Alveolar macrophages transport pathogens to lung draining lymph nodes," The Journal of Immunology, vol. 183, no. 3, pp. 1983-1989, 2009.

[15] G. B. Toews, W. C. Vial, M. M. Dunn et al., "The accessory cell function of human alveolar macrophages in specific T cell proliferation," The Journal of Immunology, vol. 132, no. 1, pp. 181-186, 1984.

[16] C. R. Lyons, E. J. Ball, G. B. Toews, J. C. Weissler, P. Stastny, and M. F. Lipscomb, "Inability of human alveolar macrophages to stimulate resting T cells correlates with decreased antigen-specific T cell-macrophage binding," The Journal of Immunology, vol. 137, no. 4, pp. 1173-1180, 1986.

[17] G. Franke-Ullmann, C. Pfortner, P. Walter, C. Steinmuller, M. L. Lohmann-Matthes, and L. Kobzik, "Characterization of murine lung interstitial macrophages in comparison with alveolar macrophages in vitro," The Journal of Immunology, vol. 157, no. 7, pp. 3097-3104, 1996.

[18] D. Bedoret, H. Wallemacq, T. Marichal et al., "Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice," Journal of Clinical Investigation, vol. 119, no. 12, pp. 3723-3738, 2009.

[19] G. M. Green, "The J. Burns Amberson lecture--in defense of the lung," American Review of Respiratory Disease, vol. 102, no. 5, pp. 691-703, 1970.

[20] R. L. Blumenthal, D. E. Campbell, P. Hwang, R. H. DeKruyff, L. R. Frankel, and D. T. Umetsu, "Human alveolar macrophages induce functional inactivation in antigen-specific CD4 T cells," Journal of Allergy and Clinical Immunology, vol. 107, no. 2, pp. 258-264, 2001.

[21] T. Thepen, N. Van Rooijen, and G. Kraal, "Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice," Journal of Experimental Medicine, vol. 170, no. 2, pp. 499-509, 1989.

[22] U. Maus, M. A. Koay, T. Delbeck et al., "Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice," American Journal of Physiology--Lung Cellular and Molecular Physiology, vol. 282, no. 6, pp. L1245-L1252, 2002.

[23] S. Hashimoto, J. F. Pittet, K. Hong et al., "Depletion of alveolar macrophages decreases neutrophil chemotaxis to pseudomonas airspace infections," American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 270, 5, Part 1, pp. L819-L828, 1996.

[24] B. Beck-Schimmer, R. Schwendener, T. Pasch, L. Reyes, C. Booy, and R. C. Schimmer, "Alveolar macrophages regulate neutrophil recruitment in endotoxin-induced lung injury," Respiratory Research, vol. 6, no. 1, p. 61, 2005.

[25] J. R. Hoidal, D. Schmeling, and P. K. Peterson, "Phagocytosis, bacterial killing, and metabolism by purified human lung phagocytes," The Journal of Infectious Diseases, vol. 144, no. 1, pp. 61-71, 1981.

[26] E. L. Gautier, T. Shay, J. Miller et al., "Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages," Nature Immunology, vol. 13, no. 11, pp. 1118-1128, 2012.

[27] M. Lagranderie, M. A. Nahori, A. M. Balazuc et al., "Dendritic cells recruited to the lung shortly after intranasal delivery of Mycobacterium bovis BCG drive the primary immune response towards a type 1 cytokine production," Immunology, vol. 108, no. 3, pp. 352-364, 2003.

[28] M. Fathi, A. Johansson, M. Lundborg, L. Orre, C. M. Skold, and P. Camner, "Functional and morphological differences between human alveolar and interstitial macrophages," Experimental and Molecular Pathology, vol. 70, no. 2, pp. 77-82, 2001.

[29] S. Prokhorova, N. Lavnikova, and D. L. Laskin, "Functional characterization of interstitial macrophages and subpopulations of alveolar macrophages from rat lung," Journal of Leukocyte Biology, vol. 55, no. 2, pp. 141-146, 1994.

[30] H.-W. Liu, A. Anand, K. Bloch, D. Christiani, and R. Kradin, "Expression of inducible nitric oxide synthase by macrophages in rat lung," American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 1, pp. 223-228, 1997.

[31] M. A. Spiteri, S. W. Clarke, and L. W. Poulter, "Isolation of phenotypically and functionally distinct macrophage subpopulations from human bronchoalveolar lavage," European Respiratory Journal, vol. 5, no. 6, pp. 717-726, 1992.

[32] D. B. Chandler, W. C. Fuller, R. M. Jackson, and J. D. Fulmer, "Fractionation of rat alveolar macrophages by isopycnic centrifugation: morphological, cytochemical, biochemical, and functional properties," Journal of Leukocyte Biology, vol. 39, no. 4, pp. 371-383, 1986.

[33] T. S. Haugen, B. Nakstad, and T. Lyberg, "Heterogeneity of procoagulant activity and cytokine release in subpopulations of alveolar macrophages and monocytes," Inflammation, vol. 23, no. 1, pp. 15-23, 1999.

[34] B. S. Zwilling, L. B. Campolito, and N. A. Reiches, "Alveolar macrophage subpopulations identified by differential centrifugation on a discontinuous albumin density gradient," American Review of Respiratory Disease, vol. 125, no. 4, pp. 448-452, 1982.

[35] A. Holian, J. H. Dauber, M. S. Diamond, and R. P. Daniele, "Separation of bronchoalveolar cells from the guinea pig on continuous gradients of Percoll: functional properties of fractionated lung macrophages," Journal of the Reticuloendothelial Society, vol. 33, no. 2, pp. 157-164, 1983.

[36] W. J. Calhoun and S. M. Salisbury, "Heterogeneity in cell recovery and superoxide production in buoyant, density-defined subpopulations of human alveolar macrophages from healthy volunteers and sarcoidosis patients," The Journal of Laboratory and Clinical Medicine, vol. 114, no. 6, pp. 682-690, 1989.

[37] J. Shellito and H. B. Kaltreider, "Heterogeneity of immunologic function among subfractions of normal rat alveolar macrophages: II. Activation as a determinant of functional activity," American Review of Respiratory Disease, vol. 131, no. 5, pp. 678-683, 1985.

[38] J. Shellito and H. B. Kaltreider, "Heterogeneity of immunologic function among subfractions of normal rat alveolar macrophages," American Review of Respiratory Disease, vol. 129, no. 5, pp. 747-753, 1984.

[39] M. A. Murphy and H. B. Herscowitz, "Heterogeneity among alveolar macrophages in humoral and cell-mediated immune responses: separation of functional subpopulations by density gradient centrifugation on Percoll," Journal of Leukocyte Biology, vol. 35, no. 1, pp. 39-54, 1984.

[40] V. A. Gant and A. S. Hamblin, "Human bronchoalveolar macrophage heterogeneity demonstrated by histochemistry, surface markers and phagocytosis," Clinical & experimental immunology, vol. 60, no. 3, pp. 539-545, 1985.

[41] R. G. Sitrin, P. G. Brubaker, J. E. Shellito, and H. B. Kaltreider, "The distribution of procoagulant and plasminogen activator activities among density fractions of normal rabbit alveolar macrophages," American Review of Respiratory Disease, vol. 133, no. 3, pp. 468-472, 1986.

[42] K. Sakai, H. Moriya, A. Ueyama, and Y. Kishino, "Morphological heterogeneity among fractionated alveolar macrophages in their release of lysosomal enzymes," Cellular and Molecular Biology, vol. 37, no. 1, pp. 85-94, 1991.

[43] D. K. Nayak, F. Zhou, M. Xu et al., "Long-term persistence of donor alveolar macrophages in human lung transplant recipients that influences donor-specific immune responses," American Journal of Transplantation, vol. 16, no. 8, pp. 2300-2311, 2016.

[44] I. Egufluz-Gracia, H. H. L. Schultz, L. I. B. Sikkeland et al., "Long-term persistence of human donor alveolar macrophages in lung transplant recipients," Thorax, vol. 71, no. 11, pp. 1006-1011, 2016.

[45] D. Hashimoto, A. Chow, C. Noizat et al., "Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes," Immunity, vol. 38, no. 4, pp. 792-804, 2013.

[46] U. A. Maus, S. Janzen, G. Wall et al., "Resident alveolar macrophages are replaced by recruited monocytes in response to endotoxin-induced lung inflammation," American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 2, pp. 227-235, 2006.

[47] J. D. Tarling, H. S. Lin, and S. Hsu, "Self-renewal of pulmonary alveolar macrophages: evidence from radiation chimera studies," Journal of Leukocyte Biology, vol. 42, no. 5, pp. 443-446, 1987.

[48] E. Thomas, R. Ramberg, G. Sale, R. Sparkes, and D. Golde, "Direct evidence for a bone marrow origin of the alveolar macrophage in man," Science, vol. 192, no. 4243, pp. 1016-1018, 1976.

[49] C. Steinmuller, G. Franke-Ullmann, M. L. Lohmann-Matthes, and A. Emmendorffer, "Local activation of nonspecific defense against a respiratory model infection by application of interferon- y: comparison between rat alveolar and interstitial lung macrophages," American Journal of Respiratory Cell and Molecular Biology, vol. 22, no. 4, pp. 481-490, 2000.

[50] N. Lavnikova, S. Prokhorova, L. Helyar, and D. L. Laskin, "Isolation and partial characterization of subpopulations of alveolar macrophages, granulocytes, and highly enriched interstitial macrophages from rat lung," American Journal of Respiratory Cell and Molecular Biology, vol. 8, no. 4, pp. 384-392, 1993.

[51] D. B. Chandler and A. L. Brannen, "Interstitial macrophage subpopulations: responsiveness to chemotactic stimuli," Tissue and Cell, vol. 22, no. 4, pp. 427-434, 1990.

[52] D. B. Chandler, G. Bayles, and W. C. Fuller, "Prostaglandin synthesis and release by subpopulations of rat interstitial macrophages," American Review of Respiratory Disease, vol. 138, no. 4, pp. 901-907, 1988.

[53] D. B. Chandler, J. I. Kennedy, and J. D. Fulmer, "Studies of membrane receptors, phagocytosis, and morphology of subpopulations of rat lung interstitial macrophages," American Review of Respiratory Disease, vol. 134, no. 3, pp. 542-547, 1986.

[54] P. G. Holt, L. A. Warner, and J. M. Papadimitriou, "Alveolar macrophages: functional heterogeneity within macrophage populations from rat lung," Australian Journal of Experimental Biology and Medical Science, vol. 60, no. 6, pp. 607-618, 1982.

[55] N. Bilyk, J. S. Mackenzie, J. M. Papadimitriou, and P. G. Holt, "Functional studies on macrophage populations in the airways and the lung wall of SPF mice in the steady-state and during respiratory virus infection," Immunology, vol. 65, no. 3, pp. 417-425, 1988.

[56] R. J. Sebring and B. E. Lehnert, "Morphometric comparisons of rat alveolar macrophages, pulmonary interstitial macrophages, and blood monocytes," Experimental Lung Research, vol. 18, no. 4, pp. 479-496, 1992.

[57] J. S. Warren, R. G. Kunkel, K. J. Johnson, and P. A. Ward, "Comparative O2-. responses of lung macrophages and blood phagocytic cells in the rat. Possible relevance to IgA immune complex induced lung injury," Laboratory Investigation, vol. 57, no. 3, pp. 311-320, 1987.

[58] L. Ziegler-Heitbrock, P. Ancuta, S. Crowe et al., "Nomenclature of monocytes and dendritic cells in blood," Blood, vol. 116, no. 16, pp. e74-e80, 2010.

[59] S. Yona, K. W. Kim, Y. Wolf et al., "Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis," Immunity, vol. 38, no. 1, pp. 79-91, 2013.

[60] F. Geissmann, S. Jung, and D. R. Littman, "Blood monocytes consist of two principal subsets with distinct migratory properties," Immunity, vol. 19, no. 1, pp. 71-82, 2003.

[61] L. M. Carlin, E. G. Stamatiades, C. Auffray et al., "Nr4a1-dependent Ly6Clow monocytes monitor endothelial cells and orchestrate their disposal," Cell, vol. 153, no. 2, pp. 362-375, 2013.

[62] C. Auffray, D. Fogg, M. Garfa et al., "Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior," Science, vol. 317, no. 5838, pp. 666-670, 2007.

[63] E. Segura, M. Touzot, A. Bohineust et al., "Human inflammatory dendritic cells induce Th17 cell differentiation," Immunity, vol. 38, no. 2, pp. 336-348, 2013.

[64] M. Guilliams, F. Ginhoux, C. Jakubzick et al., "Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny," Nature Reviews Immunology, vol. 14, no. 8, pp. 571-8, 2014.

[65] C. V. Jakubzick, G. J. Randolph, and P. M. Henson, "Monocyte differentiation and antigen-presenting functions," Nature Reviews Immunology, vol. 17, no. 6, pp. 349-362, 2017.

[66] M. A. Ingersoll, R. Spanbroek, C. Lottaz et al., "Comparison of gene expression profiles between human and mouse monocyte subsets," Blood, vol. 115, no. 3, pp. e10-e19, 2010.

[67] J. Hettinger, D. M. Richards, J. Hansson et al., "Origin of monocytes and macrophages in a committed progenitor," Nature Immunology, vol. 14, no. 8, pp. 821-830, 2013.

[68] A. M. Zawada, K. S. Rogacev, B. Rotter et al., "SuperSAGE evidence for [CD14.sup.+]+[CD16.sup.+] monocytes as a third monocyte subset," Blood, vol. 118, no. 12, pp. e50-e61, 2011.

[69] K.-U. Belge, F. Dayyani, A. Horelt et al., "The proinflammatory [CD14.sup.+][CD16.sup.+]DR++ monocytes are a major source of TNF," The Journal of Immunology, vol. 168, no. 7, pp. 3536-3542, 2002.

[70] A.-C. Villani, R. Satija, G. Reynolds et al., "Single-cell RNAseq reveals new types of human blood dendritic cells, monocytes, and progenitors," Science, vol. 356, no. 6335, article eaah4573, 2017.

[71] J. C. Hogg, "Pathophysiology of airflow limitation in chronic obstructive pulmonary disease," Lancet, vol. 364, no. 9435, pp. 709-721, 2004.

[72] A. S. Gershon, L. Warner, P. Cascagnette, J. C. Victor, and T. To, "Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study," Lancet, vol. 378, no. 9795, pp. 991-996, 2011.

[73] Global Initiative for Chronic Obstructive Lung Disease, "GOLD 2017 global strategy for the diagnosis, management and prevention of COPD," 2017, http://goldcopd.org/gold2017-global-strategy- diagnosis-management-prevention- copd/.

[74] C. Kim, K. H. Yoo, C. K. Rhee et al., "Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea," The International Journal of Tuberculosis and Lung Disease, vol. 18, no. 6, pp. 737-743, 2014.

[75] W.-S. Kelvin Teo, W.-S. Tan, W.-F. Chong et al., "Economic burden of chronic obstructive pulmonary disease," Respirology, vol. 17, no. 1, pp. 120-126, 2012.

[76] P. Lou, Y. Zhu, P. Chen et al., "Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study," BMC Public Health, vol. 12, no. 1, p. 287, 2012.

[77] C. D. Mathers and D. Loncar, "Projections of global mortality and burden of disease from 2002 to 2030," PLoS Medicine, vol. 3, no. 11, article e442, 2006.

[78] C. J. L. Murray and A. D. Lopez, "Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study," Lancet, vol. 349, no. 9064, pp. 1498-1504, 1997.

[79] J. L. Lopez-Campos, W. Tan, and J. B. Soriano, "Global burden of COPD," Respirology, vol. 21, no. 1, pp. 14-23, 2016.

[80] D. M. Mannino and A. S. Buist, "Global burden of COPD: risk factors, prevalence, and future trends," Lancet, vol. 370, no. 9589, pp. 765-773, 2007.

[81] D. Petrescu, F. Biciusca, V. Voican, C. Petrescu, I. C. Ciobanu, and D. Tudorascu, "The clinical implications of the Alpha 1antitrypsin deficiency," Current Health Sciences Journal, vol. 39, no. 3, 2013.

[82] N. Mercado, K. Ito, and P. J. Barnes, "Accelerated ageing of the

lung in COPD: new concepts," Thorax, vol. 70, no. 5, pp. 482-489, 2015.

[83] V. Amsellem, G. Gary-Bobo, E. Marcos et al., "Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 12, pp. 1358-1366, 2011.

[84] C. M. Freeman, F. J. Martinez, M. L. K. Han et al., "Lung CD8+ T cells in COPD have increased expression of bacterial TLRs," Respiratory Research, vol. 14, no. 1, p. 13, 2013.

[85] J. Nadigel, D. Prefontaine, C. J. Baglole et al., "Cigarette smoke increases TLR4 and TLR9 expression and induces cytokine production from [CD8.sup.+] T cells in chronic obstructive pulmonary disease," Respiratory Research, vol. 12, no. 1, p. 149, 2011.

[86] W. Gao, L. Li, Y. Wang et al., "Bronchial epithelial cells: the key effector cells in the pathogenesis of chronic obstructive pulmonary disease?," Respirology, vol. 20, no. 5, pp. 722-729, 2015.

[87] E. Doz, N. Noulin, E. Boichot et al., "Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent," The Journal of Immunology, vol. 180, no. 2, pp. 1169-1178, 2008.

[88] T. Mio, D. J. Romberger, A. B. Thompson, R. A. Robbins, A. Heires, and S. I. Rennard, "Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells," American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 5, pp. 1770-1776, 1997.

[89] A. Pesci, B. Balbi, M. Majori et al., "Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease," European Respiratory Journal, vol. 12, no. 2, pp. 380-386, 1998.

[90] V. M. Keatings, P. D. Collins, D. M. Scott, and P. J. Barnes, "Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma," American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 2, pp. 530-534, 1996.

[91] J.-L. Corhay, M. Henket, D. Nguyen, B. Duysinx, J. Sele, and R. Louis, "Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD," Chest, vol. 136, no. 4, pp. 1047-1054, 2009.

[92] S. L. Traves, S. V. Culpitt, R. E. Russell, P. J. Barnes, and L. E. Donnelly, "Increased levels of the chemokines GROa and MCP-1 in sputum samples from patients with COPD," Thorax, vol. 57, no. 7, pp. 590-595, 2002.

[93] D. Morrison, I. Rahman, S. Lannan, and W. MacNee, "Epithelial permeability, inflammation, and oxidant stress in the air spaces of smokers," American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 2, pp. 473-479, 1999.

[94] A. K. Ravi, S. Khurana, J. Lemon et al., "Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum," Respiratory Research, vol. 15, no. 1, p. 103, 2014.

[95] A. Di Stefano, P. Maestrelli, A. Roggeri et al., "Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis," American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 3, pp. 803-810, 1994.

[96] H. Takizawa, M. Tanaka, K. Takami et al., "Increased expression of transforming growth factor-[beta] 1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD)," American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 6, pp. 1476-1483, 2001.

[97] D. Stanescu, A. Sanna, C. Veriter et al., "Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils," Thorax, vol. 51, no. 3, pp. 267-271, 1996.

[98] A. F. Ofulue and M. Ko, "Effects of depletion of neutrophils or macrophages on development of cigarette smokeinduced emphysema," American Journal of Physiology--Lung Cellular and Molecular Physiology, vol. 277, 1, Part 1, pp. L97-L105, 1999.

[99] A. Churg, K. Zay, S. Shay et al., "Acute cigarette smokeinduced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice," American Journal of Respiratory Cell and Molecular Biology, vol. 27, no. 3, pp. 368-374, 2002.

[100] E. E. Schriver, J. M. Davidson, M. C. Sutcliffe, B. B. Swindell, and G. R. Bernard, "Comparison of elastin peptide concentrations in body fluids from healthy volunteers, smokers, and patients with chronic obstructive pulmonary disease," American Review of Respiratory Disease, vol. 145, 4, Part 1, pp. 762-766, 1992.

[101] J. V. Fahy and B. F. Dickey, "Airway mucus function and dysfunction," New England Journal of Medicine, vol. 363, no. 23, pp. 2233-2247, 2010.

[102] R. C. Hubbard, G. Fells, J. Gadek, S. Pacholok, J. Humes, and R. G. Crystal, "Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages," Journal of Clinical Investigation, vol. 88, no. 3, pp. 891-897, 1991.

[103] I. K. Demedts, K. R. Bracke, G. van Pottelberge et al., "Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 10, pp. 998-1005, 2007.

[104] F. M. Botelho, J. K. Nikota, C. M. T. Bauer et al., "Cigarette smoke-induced accumulation of lung dendritic cells is interleukin-1a-dependent in mice," Respiratory Research, vol. 13, no. 1,p. 81, 2012.

[105] G. R. Van Pottelberge, K. R. Bracke, I. K. Demedts et al., "Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD," Respiratory Research, vol. 11, no. 1, p. 35, 2010.

[106] A. V. Rogers, E. Adelroth, K. Hattotuwa, A. Dewar, and P. K. Jeffery, "Bronchial mucosal dendritic cells in smokers and ex-smokers with COPD: an electron microscopic study," Thorax, vol. 63, no. 2, pp. 108-114, 2007.

[107] S. X. Liao, T. Ding, X.-M. Rao et al., "Cigarette smoke affects dendritic cell maturation in the small airways of patients with chronic obstructive pulmonary disease," Molecular Medicine Reports, vol. 11, no. 1, pp. 219-225, 2015.

[108] M. E. Givi, P. Akbari, L. Boon et al., "Dendritic cells inversely regulate airway inflammation in cigarette smoke-exposed mice," American Journal of Physiology--Lung Cellular and Molecular Physiology, vol. 310, no. 1, pp. L95-L102, 2016.

[109] E. Arellano-Orden, C. Calero-Acuna, N. Moreno-Mata et al., "Cigarette smoke decreases the maturation of lung myeloid dendritic cells," PLoS One, vol. 11, no. 4, article e0152737, 2016.

[110] A. Zanini, A. Spanevello, S. Baraldo et al., "Decreased maturation of dendritic cells in the central airways of COPD patients is associated with VEGF, TGF-[beta] and vascularity," Respiration, vol. 87, no. 3, pp. 234-242, 2014.

[111] P. Stoll, M. Ulrich, K. Bratke, K. Garbe, J. C. Virchow, and M. Lommatzsch, "Imbalance of dendritic cell co-stimulation in COPD," Respiratory Research, vol. 16, no. 1, p. 19, 2015.

[112] M. Tsoumakidou, S. Tousa, M. Semitekolou et al., "Tolerogenic signaling by pulmonary [CD1c.sup.+] dendritic cells induces regulatory T cells in patients with chronic obstructive pulmonary disease by IL-27/IL-10/inducible costimulator ligand," Journal of Allergy and Clinical Immunology, vol. 134, no. 4, pp. 944-954.e8, 2014.

[113] S. Grumelli, D. B. Corry, L. Z. Song et al., "An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema," PLoS Medicine, vol. 1, no. 1, article e8, 2004.

[114] C. Pridgeon, L. Bugeon, L. Donnelly et al., "Regulation of IL-17 in chronic inflammation in the human lung," Clinical Science, vol. 120, no. 12, pp. 515-524, 2011.

[115] M. Ponce-Gallegos, A. Ramirez-Venegas, and R. Falfan-Valencia, "Th17 profile in COPD exacerbations," International Journal of Chronic Obstructive Pulmonary Disease, vol. 12, pp. 1857-1865, 2017.

[116] M. Saetta, M. Mariani, P. Panina-Bordignon et al., "Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 10, pp. 1404-1409, 2002.

[117] R. A. Urbanowicz, J. R. Lamb, I. Todd, J. M. Corne, and L. C. Fairclough, "Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients," Respiratory Research, vol. 11, no. 1, p. 76, 2010.

[118] J. H. J. Vernooy, G. M. Moller, R. J. van Suylen et al., "Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 5, pp. 464-472, 2007.

[119] G. Chrysofakis, N. Tzanakis, D. Kyriakoy et al., "Perforin expression and cytotoxic activity of sputum [CD8.sup.+] lymphocytes in patients with COPD," Chest, vol. 125, no. 1, pp. 71-76, 2004.

[120] J. Majo, H. Ghezzo, and M. G. Cosio, "Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema," European Respiratory Journal, vol. 17, no. 5, pp. 946-953, 2001.

[121] F. R. D'Alessio, K. Tsushima, N. R. Aggarwal et al., "[CD4.sup.+] [CD25.sup.+][Foxp3.sup.+] Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury," Journal of Clinical Investigation, vol. 119, no. 10, pp. 2898-2913, 2009.

[122] B. Barcelo, J. Pons, J. M. Ferrer, J. Sauleda, A. Fuster, and A. G. N. Agusti, "Phenotypic characterisation of Tlymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking," European Respiratory Journal, vol. 31, no. 3, pp. 555-562, 2008.

[123] A. Di Stefano, G. Caramori, A. Barczyk et al., "Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD," Thorax, vol. 69, no. 6, pp. 516-524, 2014.

[124] B. W. A. van der Strate, D. S. Postma, C. A. Brandsma et al., "Cigarette smoke-induced emphysema: A role for the B cell?," American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 7, pp. 751-758, 2006.

[125] F. Polverino, S. Baraldo, E. Bazzan et al., "A novel insight into adaptive immunity in chronic obstructive pulmonary disease: B cell activating factor belonging to the tumor necrosis factor family," American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 8, pp. 1011-1019, 2010.

[126] C. S. Berenson, R. L. Kruzel, E. Eberhardt et al., "Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations," Thorax, vol. 69, no. 9, pp. 811-818, 2014.

[127] G. G. Brusselle, T. Demoor, K. R. Bracke, C.-A. Brandsma, and W. Timens, "Lymphoid follicles in (very) severe COPD: beneficial or harmful?," European Respiratory Journal, vol. 34, no. 1, pp. 219-230, 2009.

[128] T. A. R. Seemungal, G. C. Donaldson, E. A. Paul, J. C. Bestall, D. J. Jeffries, and J. A. Wedzicha, "Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 5, pp. 1418-1422, 1998.

[129] D. S. Garcha, S. J. Thurston, A. R. C. Patel et al., "Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD," Thorax, vol. 67, no. 12, pp. 1075-1080, 2012.

[130] S. Sethi, N. Evans, B. J. B. Grant, and T. F. Murphy, "New strains of bacteria and exacerbations of chronic obstructive pulmonary disease," New England Journal of Medicine, vol. 347, no. 7, pp. 465-471, 2002.

[131] R. Pela, F. Marchesani, C. Agostinelli et al., "Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation," Monaldi Archives for Chest Disease, vol. 53, no. 3, pp. 262-267, 1998.

[132] N. Soler, A. Torres, S. Ewig et al., "Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation," American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 5, pp. 1498-1505, 1998.

[133] M. Singh, S. H. Lee, P. Porter et al., "Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease," Journal of Allergy and Clinical Immunology, vol. 125, no. 6, pp. 1369-1378.e2, 2010.

[134] J. D. Beckham, A. Cadena, J. Lin et al., "Respiratory viral infections in patients with chronic, obstructive pulmonary disease," Journal of Infection, vol. 50, no. 4, pp. 322-330, 2005.

[135] S. Sethi, P. Mallia, and S. L. Johnston, "New paradigms in the pathogenesis of chronic obstructive pulmonary disease II," Proceedings of the American Thoracic Society, vol. 6, no. 6, pp. 532-534, 2009.

[136] M.-J. Kang, C. G. Lee, J. Y. Lee et al., "Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice," Journal of Clinical Investigation, vol. 118, no. 8, pp. 2771-2784, 2008.

[137] C. Selby, E. Drost, S. Lannan, P. K. Wraith, and W. Macnee, "Neutrophil retention in the lungs of patients with chronic obstructive pulmonary disease," American Review of Respiratory Disease, vol. 143, no. 6, pp. 1359-1364, 1991.

[138] S. Sethi, C. Wrona, B. J. B. Grant, and T. F. Murphy, "Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 4, pp. 448-453, 2004.

[139] S. Sethi, J. Maloney, L. Grove, C. Wrona, and C. S. Berenson, "Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 9, pp. 991-998, 2006.

[140] K. Fujimoto, M. Yasuo, K. Urushibata, M. Hanaoka, T. Koizumi, and K. Kubo, "Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease," European Respiratory Journal, vol. 25, no. 4, pp. 640-646, 2005.

[141] B. Meshi, T. Z. Vitalis, D. Ionescu et al., "Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response," American Journal of Respiratory Cell and Molecular Biology, vol. 26, no. 1, pp. 52-57, 2002.

[142] A. di Stefano, A. Capelli, M. Lusuardi et al., "Severity of airflow limitation is associated with severity of airway inflammation in smokers," American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 4, pp. 1277-1285, 1998.

[143] A. Heguy, T. P. O'Connor, K. Luettich et al., "Gene expression profiling of human alveolar macrophages of phenotypically normal smokers and nonsmokers reveals a previously unrecognized subset of genes modulated by cigarette smoking," Journal of Molecular Medicine, vol. 84, no. 4, pp. 318-328, 2006.

[144] J. Xue, S. V. Schmidt, J. Sander et al., "Transcriptome-based network analysis reveals a spectrum model of human macrophage activation," Immunity, vol. 40, no. 2, pp. 274-288, 2014.

[145] H. Chen, M. J. Cowan, J. D. Hasday, S. N. Vogel, and A. E. Medvedev, "Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-[kappa]B in alveolar macrophages stimulated with TLR2 and TLR4 agonists," The Journal of Immunology, vol. 179, no. 9, pp. 6097-6106, 2007.

[146] R. Aldonyte, L. Jansson, E. Piitulainen, and S. Janciauskiene, "Circulating monocytes from healthy individuals and COPD patients," Respiratory Research, vol. 4, no. 1, p. 11, 2003.

[147] S. Bozinovski, R. Vlahos, Y. Zhang et al., "Carbonylation caused by cigarette smoke extract is associated with defective macrophage immunity," American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 2, pp. 229-236, 2011.

[148] H. J. Metcalfe, S. Lea, D. Hughes, R. Khalaf, K. Abbott-Banner, and D. Singh, "Effects of cigarette smoke on Toll-like receptor (TLR) activation of chronic obstructive pulmonary disease (COPD) macrophages," Clinical & Experimental Immunology, vol. 176, no. 3, pp. 461-472, 2014.

[149] M. Frankenberger, C. Eder, T. P. Hofer et al., "Chemokine expression by small sputum macrophages in COPD," Molecular Medicine, vol. 17, no. 7-8, pp. 1-770, 2011.

[150] S. Hodge, G. Matthews, V. Mukaro et al., "Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine," American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 5, pp. 673-681, 2011.

[151] I. Doyle, M. Ratcliffe, A. Walding et al., "Differential gene expression analysis in human monocyte-derived macrophages: impact of cigarette smoke on host defence," Molecular Immunology, vol. 47, no. 5, pp. 1058-1065, 2010.

[152] G. J. Gaschler, C. C. J. Zavitz, C. M. T. Bauer et al., "Cigarette smoke exposure attenuates cytokine production by mouse alveolar macrophages," American Journal of Respiratory Cell and Molecular Biology, vol. 38, no. 2, pp. 218-226, 2008.

[153] W. I. de Boer, J. K. Sont, A. van Schadewijk, J. Stolk, J. H. van Krieken, and P. S. Hiemstra, "Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD," The Journal of Pathology, vol. 190, no. 5, pp. 619-626, 2000.

[154] R. Shaykhiev, A. Krause, J. Salit et al., "Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease," The Journal of Immunology, vol. 183, no. 4, pp. 2867-2883, 2009.

[155] M. A. Birrell, S. Wong, M. C. Catley, and M. G. Belvisi, "Impact of tobacco-smoke on key signaling pathways in the innate immune response in lung macrophages," Journal of Cellular Physiology, vol. 214, no. 1, pp. 27-37, 2008.

[156] R. Taha, R. Olivenstein, T. Utsumi et al., "Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 2, pp. 636-640, 2000.

[157] K. Karimi, H. Sarir, E. Mortaz et al., "Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages," Respiratory Research, vol. 7, no. 1, p. 66, 2006.

[158] J. C. Todt, C. M. Freeman, J. P. Brown et al., "Smoking decreases the response of human lung macrophages to double-stranded RNA by reducing TLR3 expression," Respiratory Research, vol. 14, no. 1, p. 33, 2013.

[159] J.-H. Yu, L. Long, Z.-X. Luo, L.-M. Li, and J.-R. You, "Anti-inflammatory role of microRNA let-7c in LPS treated alveolar macrophages by targeting STAT3," Asian Pacific Journal of Tropical Medicine, vol. 9, no. 1, pp. 72-75, 2016.

[160] C. Tan, L. Xuan, S. Cao, G. Yu, Q. Hou, and H. Wang, "Decreased histone deacetylase 2 (HDAC2) in peripheral blood monocytes (PBMCs) of COPD patients," PLoS One, vol. 11, no. 1, article e0147380, 2016.

[161] K. Ito, M. Ito, W. M. Elliott et al., "Decreased histone deacetylase activity in chronic obstructive pulmonary disease," New England Journal of Medicine, vol. 352, no. 19, pp. 1967-1976, 2005.

[162] S.-R. Yang, A. S. Chida, M. R. Bauter et al., "Cigarette smoke induces proinflammatory cytokine release by activation of NF-[kappa]B and posttranslational modifications of histone deacetylase in macrophages," American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 291, no. 1, pp. L46-L57, 2006.

[163] D. F. Church and W. A. Pryor, "Free-radical chemistry of cigarette smoke and its toxicological implications," Environmental Health Perspectives, vol. 64, pp. 111-126, 1985.

[164] W. A. Pryor and K. Stone, "Oxidants in cigarette smoke radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite," Annals of the New York Academy of Sciences, vol. 686, pp. 12-27, 1993.

[165] H. Sarir, E. Mortaz, K. Karimi et al., "Cigarette smoke regulates the expression of TLR4 and IL-8 production by human macrophages," Journal of Inflammation, vol. 6, no. 1, p. 12, 2009.

[166] T. Muller and S. Gebel, "The cellular stress response induced by aqueous extracts of cigarette smoke is critically dependent on the intracellular glutathione concentration," Carcinogenesis, vol. 19, no. 5, pp. 797-801, 1998.

[167] P. Maestrelli, C. Paska, M. Saetta et al., "Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients," European Respiratory Journal, vol. 21, no. 6, pp. 971-6, 2003.

[168] K. Ito, S. Lim, G. Caramori, K. F. Chung, P. J. Barnes, and I. M. Adcock, "Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages," The FASEB Journal, vol. 15, no. 6, pp. 1110-1112, 2001.

[169] C. Trocme, C. Deffert, J. Cachat et al., "Macrophage-specific NOX2 contributes to the development of lung emphysema through modulation of SIRT1/MMP-9 pathways," The Journal of Pathology, vol. 235, no. 1, pp. 65-78, 2015.

[170] K. Aoshiba, J. Tamaoki, and A. Nagai, "Acute cigarette smoke exposure induces apoptosis of alveolar macrophages," American Journal of Physiology--Lung Cellular and Molecular Physiology, vol. 281, no. 6, pp. L1392-L1401, 2001.

[171] S. M. Cloonan, S. Mumby, I. M. Adcock, A. M. K. Choi, K. F. Chung, and G. J. Quinlan, "The "iron"-y of iron overload and iron deficiency in chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 196, no. 9, pp. 1103-1112, 2017.

[172] S. Mohan, T. Ho, M. Kjarsgaard et al., "Hemosiderin in sputum macrophages may predict infective exacerbations of chronic obstructive pulmonary disease: a retrospective observational study," BMC Pulmonary Medicine, vol. 17, no. 1, p. 60, 2017.

[173] Q. Philippot, G. Deslee, T. L. Adair-Kirk et al., "Increased iron sequestration in alveolar macrophages in chronic obtructive pulmonary disease," PLoS One, vol. 9, no. 5, article e96285, 2014.

[174] L. J. Wesselius, M. E. Nelson, and B. S. Skikne, "Increased release of ferritin and iron by iron-loaded alveolar macrophages in cigarette smokers," American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 3, pp. 690-695,1994.

[175] M. W. Plautz, K. Bailey, and L. J. Wesselius, "Influence of cigarette smoking on crocidolite-induced ferritin release by human alveolar macrophages," Journal of Laboratory and Clinical Medicine, vol. 136, no. 6, pp. 449-456, 2000.

[176] R. K. Thimmulappa, X. Gang, J.-H. Kim, T. E. Sussan, J. L. Witztum, and S. Biswal, "Oxidized phospholipids impair pulmonary antibacterial defenses: evidence in mice exposed to cigarette smoke," Biochemical and Biophysical Research Communications, vol. 426, no. 2, pp. 253-259, 2012.

[177] E. L. Beckett, R. L. Stevens, A. G. Jarnicki et al., "A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis," Journal of Allergy and Clinical Immunology, vol. 131, no. 3, pp. 752-762.e7, 2013.

[178] H. Li, T. Yang, Q. Ning et al., "Cigarette smoke extract-treated mast cells promote alveolar macrophage infiltration and polarization in experimental chronic obstructive pulmonary disease," Inhalation Toxicology, vol. 27, no. 14, pp. 822-831, 2015.

[179] R. Foronjy, T. Nkyimbeng, A. Wallace et al., "Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin," American Journal of Physiology--Lung Cellular and Molecular Physiology, vol. 294, no. 6, pp. L1149-L1157, 2008.

[180] A. Punturieri, S. Filippov, E. Allen et al., "Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages," The Journal of Experimental Medicine, vol. 192, no. 6, pp. 789-800, 2000.

[181] R. E. K. Russell, A. Thorley, S. V. Culpitt et al., "Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases," American Journal of Physiology--Lung Cellular and Molecular Physiology, vol. 283, no. 4, pp. L867-L873, 2002.

[182] R. D. Hautamaki, D. K. Kobayashi, R. M. Senior, and S. D. Shapiro, "Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice," Science, vol. 277, no. 5334, pp. 2002-2004, 1997.

[183] A. M. Houghton, P. A. Quintero, D. L. Perkins et al., "Elastin fragments drive disease progression in a murine model of emphysema," Journal of Clinical Investigation, vol. 116, no. 3, pp. 753-759, 2006.

[184] S. D. Shapiro, "The macrophage in chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 160, Supplement 1, pp. S29-S32, 1999.

[185] J. Gadek, G. Fells, and R. Crystal, "Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans," Science, vol. 206, no. 4424, pp. 1315-1316, 1979.

[186] V. Y. Reddy, Q. Y. Zhang, and S. J. Weiss, "Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages," Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 9, pp. 3849-3853, 1995.

[187] G. P. Shi, J. S. Munger, J. P. Meara, D. H. Rich, and H. A. Chapman, "Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease," The Journal of Biological Chemistry, vol. 267, no. 11, pp. 7258-7262, 1992.

[188] A. M. Wallace, A. J. Sandford, J. C. English et al., "Matrix metalloproteinase expression by human alveolar macrophages in relation to emphysema," COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 5, no. 1,pp. 13-23, 2008.

[189] G. A. Finlay, L. R. O'Driscoll, K. J. Russell et al., "Matrix metalloproteinase expression and production by alveolar macrophages in emphysema," American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 1, pp. 240-247, 1997.

[190] A. M. Wallace, L. B. Loy, R. T. Abboud et al., "Expression of matrix metalloproteinase-1 in alveolar macrophages, type II pneumocytes, and airways in smokers: relationship to lung function and emphysema," Lung, vol. 192, no. 4, pp. 467-472, 2014.

[191] L. Segura-Valdez, A. Pardo, M. Gaxiola, B. D. Uhal, C. Becerril, and M. Selman, "Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD," Chest, vol. 117, no. 3, pp. 684-694, 2000.

[192] P. G. Woodruff, L. L. Koth, Y. H. Yang et al., "A distinctive alveolar macrophage activation state induced by cigarette smoking," American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 11, pp. 1383-1392, 2005.

[193] S. Molet, C. Belleguic, H. Lena et al., "Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease," Inflammation Research, vol. 54, no. 1, pp. 31-36, 2005.

[194] K. Imai, S. S. Dalal, E. S. Chen et al., "Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema," American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 3, pp. 786-791, 2001.

[195] S. Lim, N. Roche, B. G. Oliver, W. Mattos, P. J. Barnes, and K. F. Chung, "Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10," American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 4, pp. 1355-1360, 2000.

[196] K. Krotova, G. W. Marek, R. L. Wang et al., "Alpha-1 antitrypsin-deficient macrophages have increased matriptase-mediated proteolytic activity," American Journal of Respiratory Cell and Molecular Biology, vol. 57, no. 2, pp. 238-247, 2017.

[197] A. Churg, R. D. Wang, H. Tai et al., "Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-a release," American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 8, pp. 1083-1089, 2003.

[198] S. J. Cho, M. D. Weiden, and C. G. Lee, "Chitotriosidase in the pathogenesis of inflammation, interstitial lung diseases and COPD," Allergy, Asthma & Immunology Research, vol. 7, no. 1, pp. 14-21, 2015.

[199] S. Letuve, A. Kozhich, A. Humbles et al., "Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation," The American Journal of Pathology, vol. 176, no. 2, pp. 638-649, 2010.

[200] S. Letuve, A. Kozhich, N. Arouche et al., "YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages," The Journal of Immunology, vol. 181, no. 7, pp. 5167-5173, 2008.

[201] M. Lundborg, S. E. Dahlen, U. Johard et al., "Aggregates of ultrafine particles impair phagocytosis of microorganisms by human alveolar macrophages," Environmental Research, vol. 100, no. 2, pp. 197-204, 2006.

[202] M. Lundborg, U. Johard, L. Lastbom, P. Gerde, and P. Camner, "Human alveolar macrophage phagocytic function is impaired by aggregates of ultrafine carbon particles," Environmental Research, vol. 86, no. 3, pp. 244-253, 2001.

[203] P. Marti-Lliteras, V. Regueiro, P. Morey et al., "Nontypeable Haemophilus influenzae clearance by alveolar macrophages is impaired by exposure to cigarette smoke," Infection and Immunity, vol. 77, no. 10, pp. 4232-4242, 2009.

[204] C. S. Berenson, M. A. Garlipp, L. J. Grove, J. Maloney, and S. Sethi, "Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease," The Journal of Infectious Diseases, vol. 194, no. 10, pp. 1375-1384, 2006.

[205] A. E. Taylor, T. K. Finney-Hayward, J. K. Quint et al., "Defective macrophage phagocytosis of bacteria in COPD," European Respiratory Journal, vol. 35, no. 5, pp. 1039-1047, 2010.

[206] C. S. Berenson, R. L. Kruzel, C. T. Wrona, M. J. Mammen, and S. Sethi, "Impaired innate COPD alveolar macrophage responses and Toll-like receptor-9 polymorphisms," PLoS One, vol. 10, no. 9, article e0134209, 2015.

[207] C. S. Berenson, R. L. Kruzel, E. Eberhardt, and S. Sethi, "Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease," The Journal of Infectious Diseases, vol. 208, no. 12, pp. 2036-2045, 2013.

[208] A. Vecchiarelli, M. Dottorini, M. Puliti, T. Todisco, E. Cenci, and F. Bistoni, "Defective candidacidal activity of alveolar macrophages and peripheral blood monocytes from patients with chronic obstructive pulmonary disease," American Review of Respiratory Disease, vol. 143, 5, Part 1, pp. 1049-1054, 1991.

[209] F. Ferrara, D. D'Adda, M. Falchi, and L. Dall'Asta, "The macrophagic activity of patients affected by pneumonia or chronic obstructive pulmonary disease," International Journal of Tissue Reactions, vol. 18, no. 4-6, pp. 109-114, 1996.

[210] J. C. Phipps, D. M. Aronoff, J. L. Curtis, D. Goel, E. O'Brien, and P. Mancuso, "Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of Streptococcus pneumoniae," Infection and Immunity, vol. 78, no. 3, pp. 1214-1220, 2010.

[211] Y. Higashimoto, Y. Fukuchi, K. Ishida et al., "Effect of chronic tobacco smoke exposure on the function of alveolar macrophages in mice," Respiration, vol. 61, no. 1, pp. 23-27, 1994.

[212] A. Prieto, E. Reyes, E. D. Bernstein et al., "Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferon)," American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 7, pp. 1578-1583, 2001.

[213] G. Muns, I. Rubinstein, and K. C. Bergmann, "Phagocytosis and oxidative burst of blood phagocytes in chronic obstructive airway disease," Scandinavian Journal of Infectious Diseases, vol. 27, no. 4, pp. 369-373, 1995.

[214] R. W. Vandivier, P. M. Henson, and I. S. Douglas, "Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease," Chest, vol. 129, no. 6, pp. 1673-1682, 2006.

[215] P. A. Kirkham, G. Spooner, I. Rahman, and A. G. Rossi, "Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke and lipid peroxidation products," Biochemical and Biophysical Research Communications, vol. 318, no. 1, pp. 32-37, 2004.

[216] N. Minematsu, A. Blumental-Perry, and S. D. Shapiro, "Cigarette smoke inhibits engulfment of apoptotic cells by macrophages through inhibition of actin rearrangement," American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 4, pp. 474-482, 2011.

[217] O. Eltboli, M. Bafadhel, F. Hollins et al., "COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils," BMC Pulmonary Medicine, vol. 14, no. 1, p. 112, 2014.

[218] S. Hodge, G. Hodge, R. Scicchitano, P. N. Reynolds, and M. Holmes, "Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells," Immunology & Cell Biology, vol. 81, no. 4, pp. 289-296, 2003.

[219] S. Hodge, G. Hodge, J. Ahern, H. Jersmann, M. Holmes, and P. N. Reynolds, "Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease," American Journal of Respiratory Cell and Molecular Biology, vol. 37, no. 6, pp. 748-755, 2007.

[220] A. Kazeros, B.-G. Harvey, B. J. Carolan, H. Vanni, A. Krause, and R. G. Crystal, "Overexpression of apoptotic cell removal receptor MERTK in alveolar macrophages of cigarette smokers," American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 6, pp. 747-757, 2008.

[221] K. A. Serban, D. N. Petrusca, A. Mikosz et al., "Alpha-1 antitrypsin supplementation improves alveolar macrophages efferocytosis and phagocytosis following cigarette smoke exposure," PLoS One, vol. 12, no. 4, article e0176073, 2017.

[222] H. B. Tran, J. Barnawi, M. Ween et al., "Cigarette smoke inhibits efferocytosis via deregulation of sphingosine kinase signaling: reversal with exogenous S1P and the S1P analogue FTY720," Journal of Leukocyte Biology, vol. 100, no. 1, pp. 195-202, 2016.

[223] J. Barnawi, H. Jersmann, R. Haberberger, S. Hodge, and R. Meech, "Reduced DNA methylation of sphingosine-1 phosphate receptor 5 in alveolar macrophages in COPD: a potential link to failed efferocytosis," Respirology, vol. 22, no. 2, pp. 315-321, 2017.

[224] J. Barnawi, H. Tran, H. Jersmann et al., "Potential link between the sphingosine-1-phosphate (S1P) system and defective alveolar macrophage phagocytic function in chronic obstructive pulmonary disease (COPD)," PLoS One, vol. 10, no. 10, article e0122771, 2015.

[225] D. N. Petrusca, Y. Gu, J. J. Adamowicz et al., "Sphingolipid-mediated inhibition of apoptotic cell clearance by alveolar macrophages," Journal of Biological Chemistry, vol. 285, no. 51, pp. 40322-40332, 2010.

[226] M. Baqir, C. Z. Chen, R. J. Martin et al., "Cigarette smoke decreases MARCO expression in macrophages: implication in Mycoplasma pneumoniae infection," Respiratory Medicine, vol. 102, no. 11, pp. 1604-1610, 2008.

[227] J. A. Ohar, R. F. Hamilton Jr, S. Zheng et al., "COPD Is associated with a macrophage scavenger receptor-1 gene sequence variation," Chest, vol. 137, no. 5, pp. 1098-1107, 2010.

[228] M. A. Bewley, K. B. R. Belchamber, K. K. Chana et al., "Differential effects of p38, MAPK, PI3K or rho kinase inhibitors on bacterial phagocytosis and efferocytosis by macrophages in COPD," PLoS One, vol. 11, no. 9, article e0163139, 2016.

[229] T. R. Richens, D. J. Linderman, S. A. Horstmann et al., "Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA," American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 11, pp. 1011-1021, 2009.

[230] M. A. Bewley, J. A. Preston, M. Mohasin et al., "Impaired mitochondrial microbicidal responses in chronic obstructive pulmonary disease macrophages," American Journal of Respiratory and Critical Care Medicine, vol. 196, no. 7, pp. 845855, 2017.

[231] F. O. Martinez and S. Gordon, "The M1 and M2 paradigm of macrophage activation: time for reassessment," F1000Prime Reports, vol. 6, p. 13, 2014.

[232] F. Ginhoux, J. L. Schultze, P. J. Murray, J. Ochando, and S. K. Biswas, "New insights into the multidimensional concept of macrophage ontogeny, activation and function," Nature Immunology, vol. 17, no. 1, pp. 34-40, 2015.

[233] A. R. Pons, A. Noguera, D. Blanquer, J. Sauleda, J. Pons, and A. G. Agusti, "Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD," European Respiratory Journal, vol. 25, no. 4, pp. 647-652, 2005.

[234] J. M. Lofdahl, J. Wahlstrom, and C. M. Skold, "Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers," Clinical & Experimental Immunology, vol. 145, no. 3, pp. 428-437, 2006.

[235] Y. Kaku, H. Imaoka, Y. Morimatsu et al., "Overexpression of CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe chronic obstructive pulmonary disease," PLoS One, vol. 9, no. 1, article e87400, 2014.

[236] D. Droemann, T. Goldmann, T. Tiedje, P. Zabel, K. Dalhoff, and B. Schaaf, "Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients," Respiratory Research, vol. 6, no. 1, p. 68, 2005.

[237] Y. Wu, H. Xu, L. Li, W. Yuan, D. Zhang, and W. Huang, "Susceptibility to Aspergillus infections in rats with chronic obstructive pulmonary disease via deficiency function of alveolar macrophages and impaired activation of TLR2," Inflammation, vol. 39, no. 4, pp. 1310-1318, 2016.

[238] A. Koarai, S. Yanagisawa, H. Sugiura et al., "Cigarette smoke augments the expression and responses of Toll-like receptor 3 in human macrophages," Respirology, vol. 17, no. 6, pp. 1018-1025, 2012.

[239] L. I. Z. Kunz, T. S. Lapperre, J. B. Snoeck-Stroband et al., "Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD," Respiratory Research, vol. 12, no. 1, p. 34, 2011.

[240] P. Gutierrez, D. Closa, R. Piner, O. Bulbena, R. Menendez, and A. Torres, "Macrophage activation in exacerbated COPD with and without community-acquired pneumonia," European Respiratory Journal, vol. 36, no. 2, pp. 285-291, 2010.

[241] J. G. McComb, M. Ranganathan, X. H. Liu et al., "CX3CL1 up-regulation is associated with recruitment of [CX3CR1.sup.+] mononuclear phagocytes and T lymphocytes in the lungs during cigarette smoke-induced emphysema," The American Journal of Pathology, vol. 173, no. 4, pp. 949-961, 2008.

[242] L. Landsman and S. Jung, "Lung macrophages serve as obligatory intermediate between blood monocytes and alveolar macrophages," The Journal of Immunology, vol. 179, no. 6, pp. 3488-3494, 2007.

[243] L. Landsman, C. Varol, and S. Jung, "Distinct differentiation potential of blood monocyte subsets in the lung," The Journal of Immunology, vol. 178, no. 4, pp. 2000-2007, 2007.

[244] Z. Xiong, A. S. Leme, P. Ray, S. D. Shapiro, and J. S. Lee, "C[X.sub.3]CR1+ lung mononuclear phagocytes spatially confined to the interstitium produce TNF-[alpha] and IL-6 and promote cigarette smoke-induced emphysema," The Journal of Immunology, vol. 186, no. 5, pp. 3206-3214, 2011.

[245] M. Frankenberger, M. Menzel, R. Betz et al., "Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers," Clinical & Experimental Immunology, vol. 138, no. 3, pp. 507-516, 2004.

[246] K. Dhaliwal, E. Scholefield, D. Ferenbach et al., "Monocytes control second-phase neutrophil emigration in established lipopolysaccharide-induced murine lung injury," American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 6, pp. 514-524, 2012.

[247] S. Poliska, E. Csanky, A. Szanto et al., "Chronic obstructive pulmonary disease-specific gene expression signatures of alveolar macrophages as well as peripheral blood monocytes overlap and correlate with lung function," Respiration, vol. 81, no. 6, pp. 499-510, 2011.

[248] S. L. Traves, S. J. Smith, P. J. Barnes, and L. E. Donnelly, "Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2," Journal of Leukocyte Biology, vol. 76, no. 2, pp. 441-450, 2004.

[249] C. Costa, S. L. Traves, S. J. Tudhope et al., "Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD," European Respiratory Journal, vol. 47, no. 4, pp. 1093-1102, 2016.

[250] T. Tschernig, A. Rabung, M. Voss, C. Meier, R. Bals, and C. Beisswenger, "Chronic inhalation of cigarette smoke reduces phagocytosis in peripheral blood leukocytes," BMC Research Notes, vol. 8, no. 1, p. 705, 2015.

[251] S. Perez-Rial, L. del Puerto-Nevado, R. Terron-Exposito, A. Giron-Martinez, N. Gonzalez-Mangado, and G. Peces Barba, "Role of recently migrated monocytes in cigarette smoke-induced lung inflammation in different strain of mice," PLoS One, vol. 8, no. 9, article e72975, 2013.

[252] N. Chaudhuri, H. Jary, S. Lea et al., "Diesel exhaust particle exposure in vitro alters monocyte differentiation and function," PLoS One, vol. 7, no. 12, article e51107, 2012.

[253] G. C. Nicholson, R. C. Tennant, D. C. Carpenter et al., "A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist," Pulmonary Pharmacology & Therapeutics, vol. 20, no. 1, pp. 52-59, 2007.

[254] X. Dang, X. Qu, W. Wang et al., "Bioinformatic analysis of microRNA and mRNA regulation in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease," Respiratory Research, vol. 18, no. 1, p. 4, 2017.

[255] Y. Chen, P. Huang, W. Ai et al., "Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD," Journal of Inflammation, vol. 9, no. 1, p. 10, 2012.

[256] J. L. Lopez-Campos, W. Tan, and J. B. Soriano, "Global burden of COPD," Respirology, vol. 21, no. 1, pp. 14-23, 2016.

[257] A. B. van oud Alblas and R. van Furth, "Origin, kinetics, and characteristics of pulmonary macrophages in the normal steady state," Journal of Experimental Medicine, vol. 149, no. 6, pp. 1504-1518, 1979.

[258] A. d. Stefano, A. Capelli, M. Lusuardi et al., "Severity of airflow limitation is associated with severity of airway inflammation in smokers," American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 4, pp. 1277-1285, 1998.

[259] M. Saetta, A. di Stefano, P. Maestrelli et al., "Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis," American Review of Respiratory Disease, vol. 147, no. 2, pp. 301-306, 1993.

[260] R. Finkelstein, R. S. Fraser, H. Ghezzo, and M. G. Cosio, "Alveolar inflammation and its relation to emphysema in smokers," American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 5, pp. 1666-1672, 1995.

[261] W. F. Grashoff, J. K. Sont, P. J. Sterk et al., "Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages," The American Journal of Pathology, vol. 151, no. 6, pp. 1785-1790, 1997.

[262] K. Tomita, G. Caramori, S. Lim et al., "Increased [p21.sup.CIP1/WAF1] and B cell lymphoma leukemia-[x.sub.L] expression and reduced apoptosis in alveolar macrophages from smokers," American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 5, pp. 724-731, 2002.

[263] M. Beyer, K. Handler, P. Gunther et al., "Navigating disease phenotypes-a multidimensional single-cell resolution compass leads the way," Current Opinion in Systems Biology, vol. 3, pp. 147-153, 2017.

Theodore S. Kapellos (ID), (1) Kevin Bassler, (1) Anna C. Aschenbrenner, (1) Wataru Fujii (ID), (1) and Joachim L. Schultze (ID), (1,2)

(1) Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), Carl-Troll-Str. 31, 53115 Bonn, Germany

(2) Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases and University ofBonn, Sigmund-Freud-Str. 27, 53175 Bonn, Germany

Correspondence should be addressed to Theodore S. Kapellos; tkapello@uni-bonn.de and Joachim L. Schultze; j.schultze@uni-bonn.de

Received 30 July 2017; Accepted 29 November 2017; Published 18 February 2018

Academic Editor: Ethan M. Shevach

Caption: Figure 1: Murine and human lung macrophage populations under steady- state conditions. AMs reside at the airspaces of the lung, while IMs localise in the interstitial space between the alveoli and blood vessels. In both the murine and human lungs, there is also a monocyte population which enters the tissue from blood vessels. AMs are the biggest of all three lung macrophage populations, are potent phagocytes, and secrete a range of proinflammatory mediators. IMs are smaller than AMs but display comparable phagocytic capacity and ability to produce soluble factors. They are believed to serve as an intermediate step in monocyte differentiation towards AMs and demonstrate proliferative potential. Finally, monocytes are sensitive to migratory gradients and have been shown to exhibit proinflammatory mediator capacity, but no antigen presentation. The currently acceptable nomenclatures for AMs, IMs, and monocytes in mice (Mm) and humans (Hs) are indicated next to each population.

Caption: Figure 2: Lung macrophage population functions in COPD. AMs exhibit alterations in their physiological responses in COPD; the secretion of proinflammatory cytokines and chemokines is dysregulated (1). The cells undergo oxidative stress and secrete ROS and nitrite species into the lung micro-environment (2), they store intracellularly large amounts of iron (2), and they overexpress and release proteases which cause alveolar tissue destruction (3). In contrast, processes, such as phagocytosis of microbes (4) and apoptotic neutrophils or epithelial cells (5), are downregulated in AMs from patients with COPD, an observation which could explain the frequent colonisation of the lungs with bacteria and viruses in exacerbations. In the meantime, monocytes are recruited from blood vessels following chemokine gradients and contribute to disease pathology via the secretion of proinflammatory mediators and proteases. It is also believed that monocytes differentiate into macrophages via an intermediate step of IMs which morphologically and functionally resemble monocytes.

Caption: Figure 3: Future directions in COPD lung macrophage population research. Recent advances in Immunogenetics and Structural Biology make it possible to evaluate the heterogeneity of lung macrophage populations. In particular, single cell RNA sequencing can identify homogeneous macrophage subsets with distinct transcriptomes and functions. Mass cytometry can complement and validate initial findings establishing prognosis/diagnosis biomarkers for human patients with COPD. Moreover, analysis of the nuclear heterochromatin state with ATAC sequencing and subsequent validation with ChIP-sequencing can shed light on the epigenetic regulation of lung macrophage populations and highlight the molecular mechanisms responsible for their functions in vivo. Lastly, the role of AMs, IMs, and lung monocytes warrants further investigation in order to better understand the contributions of each macrophage population to COPD progression and severity. Transcriptome analysis will determine whether these populations are distinct or part of a differentiation continuum from the monocyte to the AM phenotype and will associate gene expression with unique biological processes.
Table 1: Molecules differentially expressed by AMs from
animals or patients with COPD compared to healthy controls.

Molecule family       Encoded proteins               References

Cytokines         TNF-[alpha] [down arrow],   [126, 145, 147, 148, 150-
                   IL-1B [up arrow] [down               152]
                     arrow], IL-6 [down
                     arrow], IL-10 [down
                  arrow], IL-12 [up arrow],
                  TNF-[alpha] [down arrow],
                      Il-6 [down arrow]

Chemokines         IL-8 [down arrow], CCL2    [126, 145, 147-149, 151-
                   [up arrow], CCL5 [down          154, 158, 165]
                  arrow], CCL7 [up arrow],
                   CCL13 [up arrow], CCL22
                  [up arrow], Cxcl10 [down
                     arrow], CXCL9 [down
                    arrow], CXCL10 [down
                    arrow], CXCL11 [down
                           arrow]

Chemokine         CCR2 [up arrow], CCR5 [up          [153, 154]
receptors                  arrow]

Prostaglandin      PTGS1 [up arrow], PTGS2              [156]
metabolism               [up arrow]

Oxidative           GSH [down arrow], Gsh     [147, 150, 155, 165, 167]
stress             [down arrow], iNOS [up
                  arrow], HO-1 [down arrow]

Iron metabolism    Hemosiderin [up arrow],         [172-175, 219]
                   transferrin [up arrow],
                    transferrin receptor
                   [down arrow], ferritin
                         [up arrow]

Proteinases        MMP-1 [up arrow], MMP-2       [154, 188-194, 196]
                    [up arrow], MMP-7 [up
                  arrow], MMP-9 [up arrow]
                     (SNPs), MMP-12 [up
                   arrow], matriptase [up
                           arrow]

Neutrophil            [[alpha].sub.1]-                  [185]
proteases and            Antitrypsin
inhibitors

Chitinolytic      CHIT1 [up arrow], YKL-40           [199, 200]
activity                 [up arrow]

Recognition        CD31 [down arrow], CD44         [150, 219, 226]
markers           [down arrow], CD91 [down
                  arrow], CR-3 [up arrow],
                  CR-4 [up arrow], DC-SIGN
                   [up arrow], MARCO [down
                           arrow]

Cytoskeletal       RAC1 [down arrow], VAV1           [216, 229]
rearrangements     [down arrow], RhoA [up
                           arrow]

Mitochondrial         MCL-1 [up arrow]                  [230]
stress

Integrins,        CD11a [down arrow], CD11c     [220, 227, 234, 235]
scavenger           [up arrow], CD163 [up
receptors, and    arrow], CD204 [up arrow],
adhesion           CD206 [up arrow], MSR-1
molecules         (SNPs), MERTK [up arrow]

Antigen           MHC-I [down arrow], MHC-           [150, 233]
presentation       II [down arrow], HLA-DR
molecules         [down arrow], CD80 [down
                           arrow]

Fc gamma          Fc[gamm,a]R1 [up arrow],    [126, 148, 150, 158, 165,
receptors, PRRs    CD16 [down arrow], TLR2     206, 233, 234, 236-238]
                  [down arrow], TLR3 [down
                     arrow], TLR4 [down
                  arrow], TLR5 [up arrow],
                         TLR9 (SNPs)

Table 2: Molecules differentially expressed by monocytes or IMs
from animals or patients with COPD compared to healthy controls.

Molecule family            Encoded proteins        References

Cytokines              TNF-[alpha] [down arrow],   [146, 245]
                            IL-6 [up arrow]

Chemokines               CCL2 [up arrow], IL-8     [146, 252]
                             [down arrow]

Chemokine receptors         CCR2 [up arrow]          [253]

Metalloproteinases     MMP-9 [down arrow], Mmp-    [146, 251]
                             12 [up arrow]

Antigen presentation       CD86 [down arrow]         [252]
  molecules
Integrins, PRRs        CD11b [down arrow], CD14    [146, 252]
                       [down arrow], CD54 [down
                         arrow] miR-24-3p [up
                         arrow], miR-93-5p [up
                                arrow],

MicroRNAs              miR-320a [up arrow], miR-     [254]
                           320b [up arrow],
                       miR1273g-3p [down arrow]
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Kapellos, Theodore S.; Bassler, Kevin; Aschenbrenner, Anna C.; Fujii, Wataru; Schultze, Joachim L.
Publication:Journal of Immunology Research
Date:Jan 1, 2018
Words:16416
Previous Article:Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma.
Next Article:PPAR-[gamma] Agonist Alleviates Liver and Spleen Pathology via Inducing Treg Cells during Schistosoma japonicum Infection.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |